Liquidia Q3: YUTREPIA Sales Hit $222.7M, $389.7M UTC Settlement Charge Drives $236.3M Net Loss
LQDA has more than doubled off its 52-week low of $22.31.
Summary
Liquidia's Q3 2026 10-Q shows YUTREPIA product sales of $222.7 million and a $389.7 million litigation settlement charge that drove a $236.3 million net loss, with $396.1 million of cash of which $105.4 million is restricted as collateral for the UTC letters of credit.
Key Events · Earnings and Guidance · LQDA
-
YUTREPIA Sales Reach $222.7M in Q3
Product sales, net were $222.7 million for the three months ended September 30, 2026 versus $51.7 million a year earlier, a $171.0 million increase on higher volume; nine-month sales were $523.0 million versus $58.2 million.
-
$389.7M Settlement Charge Drives Net Loss
The quarter includes a $389.7 million litigation settlement charge (net cash to be paid of $380.7 million), producing a net loss of $236.3 million, or $2.64 per share, versus a $3.5 million loss a year ago.
-
Cash $396.1M, $105.4M Now Restricted
Cash and cash equivalents were $396.1 million at September 30, 2026; as of October 23, 2026, $105.4 million was legally restricted as collateral for the $145.4 million standby letters of credit securing the remaining UTC installments.
-
HCR Cash Covenant Raised to $45M
The Seventh Amendment to the HCR agreement, given in exchange for consent to the UTC letters of credit, raised the minimum cash covenant from $15.0 million to $45.0 million with no fees and no change to payment terms.
Analysis · LQDA · Life Sciences
The commercial engine is working: product sales reached $222.7 million versus $51.7 million a year ago. The income statement, however, is dominated by the one-time $389.7 million litigation settlement charge tied to the October UTC deal, which produced a $236.3 million net loss and a $2.64 per-share loss. The balance sheet tells the more important story. Cash stood at $396.1 million on September 30, but $105.4 million of that is now legally restricted as collateral for the $145.4 million letters of credit securing the two remaining $72.7 million UTC installments due January 31 and April 30, 2027. In exchange for consenting to those letters of credit, HCR raised its minimum cash covenant from $15.0 million to $45.0 million, tightening the liquidity cushion. The settlement also strips YUTREPIA of its PH-ILD label and promotion, so the durability of the current sales run-rate is the open question management itself flags as uncertain.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $47.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $22.31 to $93.61. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.